Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Convertible Debt: 2010-2019

Historic Convertible Debt for Ani Pharmaceuticals (ANIP) over the last 7 years, with Sep 2019 value amounting to $117.6 million.

  • Ani Pharmaceuticals' Convertible Debt fell 12.33% to $117.6 million in Q3 2019 from the same period last year, while for Sep 2019 it was $117.6 million, marking a year-over-year decrease of 12.33%. This contributed to the annual value of $112.5 million for FY2018, which is 12.28% down from last year.
  • Ani Pharmaceuticals' Convertible Debt amounted to $117.6 million in Q3 2019, which was up 1.49% from $115.9 million recorded in Q2 2019.
  • In the past 5 years, Ani Pharmaceuticals' Convertible Debt registered a high of $134.1 million during Q3 2018, and its lowest value of $112.2 million during Q1 2015.
  • In the last 3 years, Ani Pharmaceuticals' Convertible Debt had a median value of $124.4 million in 2017 and averaged $123.4 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Convertible Debt increased by 6.46% in 2015, and later declined by 12.33% in 2019.
  • Over the past 5 years, Ani Pharmaceuticals' Convertible Debt (Quarterly) stood at $113.4 million in 2015, then climbed by 6.36% to $120.6 million in 2016, then increased by 6.27% to $128.2 million in 2017, then decreased by 12.28% to $112.5 million in 2018, then decreased by 12.33% to $117.6 million in 2019.
  • Its Convertible Debt was $117.6 million in Q3 2019, compared to $115.9 million in Q2 2019 and $114.2 million in Q1 2019.